Home Online Features Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with ‘Neurophet AQUA’
Press Releases
November 25, 2024

Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with ‘Neurophet AQUA’

By Neurophet

New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysisAccelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North America

bradford

The Bradford Era

email
Local & Social